Showing 6081-6090 of 8180 results for "".
- Positive Results for Guselkumab for Moderate PsO Patientshttps://practicaldermatology.com/news/positive-results-guselkumab-moderate-pso-patients/2468490/Guselkumab treatment resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, according to data presented at the 44th Annual Fall Clinical Dermatology Conferenc
- Details Revealed for Upcoming Phase 2 Study for New AD Drug from Apogeehttps://practicaldermatology.com/news/details-revealed-upcoming-phase-2-study-new-ad-drug-apogee/2468489/Apogee Therapeutics’ half-life-extended monoclonal antibody APG777 for atopic dermatitis was the subject of a poster presented by Dr. Emma Guttman-Yassky and others at the 44th Annual Fall Clinical Dermatology Conference. The poster detailed the design of the phase 2 APEX study. “IL
- 3 Oral JAK Inhibitors for Vitiligo 'Running to the Finish Line'https://practicaldermatology.com/news/3-oral-jak-inhibitors-vitiligo-running-finish-line/2468487/Recent data supporting the use of topical ruxolitinib and oral Janus kinase (JAK) inhibitors for treating vitiligo were presented by Dr. Seemal Desai and Dr. Larry Eichenfield at the 44th Annual Fall Clinical Dermatology Conference. In the TRuE-V1 and TRuE-V2 studies, for all body regions
- Lecture Updates on Abrocitinib, Povorcitinib for PNhttps://practicaldermatology.com/news/lecture-updates-abrocitinib-povorcitinib-pn/2468486/Dr. Shawn Kwatra gets goosebumps when he thinks about having two approved biologics for prurigo nodularis, (PN) he said during a session at the 44th Annual Fall Clinical Dermatology Conference. “I have to pinch myself,” Dr. Kwatra said during “Making the Connection Between Prurigo Nodulari
- Analysis: Lebrikizumab Viable Dupilumab Alternative for Moderate-to-Severe ADhttps://practicaldermatology.com/news/analysis-lebrikizumab-viable-dupilumab-alternative-moderate-severe-ad/2468484/Lebrikizumab is a viable alternative for patients with moderate-to-severe atopic dermatitis (AD) who discontinue dupilumab due to inadequate response, inability to tolerate the drug, or other reasons, according to a new study presented at the Fall Clini
- LEVEL UP: Switching from Dupilumab to Upadacitinib Promising for AD Patientshttps://practicaldermatology.com/news/level-up-switching-from-dupilumab-to-upadacitinib-promising-for-ad-patients/2468483/New research presented at the 44th Annual Fall Clinical Dermatology Conference offered compelling results from th
- Dupilumab Improves Chronic Spontaneous Urticaria Symptomshttps://practicaldermatology.com/news/dupixent-improves-chronic-spontaneous-urticaria-symptoms/2468471/Dupixent® (dupilumab) significantly reduced itch and hive activity in patients with chronic spontaneous urticaria, according to phase 3 trial data presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Annual Scientific Meeting in Boston, Massachusetts. In a pre
- Consensus Paper Addresses S. aureus Exacerbated ADhttps://practicaldermatology.com/news/consensus-paper-addresses-s-aureus-exacerbated-ad/2468445/A significant unmet need exists for a single topical atopic dermatitis (AD) therapy effective against all symptoms—including pruritis, S. aureus-driven AD exacerbation, infection, and inflammation—across AD severity levels, according to a panel of six pediatric dermatologists who participated in
- Atopic Dermatitis Linked to Peripheral Vascular Diseasehttps://practicaldermatology.com/news/atopic-dermatitis-linked-peripheral-vascular-disease/2468444/People with atopic dermatitis (AD) are almost twice as likely to develop peripheral vascular disease (PVD), Yale School of Medicine researchers found in a new study. “Associated between atopic dermatitis and peripheral vascular disease: a cross-sectional study in the All of Us Research Pro
- LEO Pharma Announced CHE Awareness Campaignhttps://practicaldermatology.com/news/leo-pharma-announced-che-awareness-campaign/2468442/LEO Pharma Inc. has launched Talk to the Hand, a disease awareness campaign for healthcare providers that highlights the risk factors, symptoms, and physical and emotional impact of chronic hand eczema (CHE)—a debilitating skin condition for which there are currently no FDA approved treatments. <